Pfizer launches Phase 3 mRNA flu vaccine study

This computer-generated image shows influenza virus hemagglutinin epitopes arrayed on a nanoparticle. [Image courtesy of NIAID]

Big Pharma behemoth Pfizer (NYSE: PFE) has dosed the first participants in a pivotal Phase 3 clinical trial to test its quadrivalent modified RNA (modRNA) influenza vaccine candidate. 

The mRNA flu vaccine study will enroll roughly 25,000 healthy U.S. adults.

Pfizer is not the only company to develop an mRNA flu vaccine. In December, Moderna (Nasdaq:MRNA) announced positive interim data from a Phase 1 study of its quadrivalent seasonal flu vaccine candidate, mRNA-1010. That data, however, disappointed investors, as mRNA-1010 had a similar performance to Sanofi’s (NSDQ:SNY) Fluzone HD flu vaccine.

Moderna’s (Nasdaq:MRNA) mRNA-1010 flu vaccine is now in a Phase 3 study. That study is fully enrolled with approximately 6,000 participants. Moderna anticipates the va…

Read more
  • 0